Citadel Advisors’s BioCardia, Inc. Warrant BCDAW Stock Holding History

Citadel Advisors’s Portfolio BCDAW Stock Details BCDAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-58,644	Closed	-$745	–	15627
2024 Q2	$745	Buy	58,644 +14,771	+34%	+$294	﹤0.01%	13924
2024 Q1	$667	Sell	43,873 -2,060	-4%	-$40	﹤0.01%	14277
2023 Q4	$574	Sell	45,933 -797	-2%	-$70	﹤0.01%	14001
2023 Q3	$8.73K	Buy	46,730 +10,658	+30%	+$5.55K	﹤0.01%	13163
2023 Q2	$27K	Buy	36,072 +5,115	+17%	+$4.46K	﹤0.01%	12459
2023 Q1	$30.3K	Buy	30,957 +10,412	+51%	+$9.11K	﹤0.01%	12727
2022 Q4	$16.6K	Buy	+20,545	New	+$12.9K	﹤0.01%	13278

Citadel Advisors's BCDAW Position: Q3 2024 in Review

Citadel Advisors sold out of BioCardia, Inc. Warrant (BCDAW) in Q3 2024, closing a stake of 58,644 shares — an estimated $745 sold.

Citadel Advisors first reported a position in BCDAW in Q4 2022 and held it in 7 quarters. The position peaked at $30.3K in Q1 2023. 0 funds tracked by Wall St. Rank hold BCDAW as of Q3 2024.

Citadel Advisors reported no remaining BioCardia, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
Citadel Advisors sold 58,644 BioCardia, Inc. Warrant shares in Q3 2024, an estimated $745.
Citadel Advisors first reported a position in BioCardia, Inc. Warrant in Q4 2022 and held it in 7 quarters.
Citadel Advisors's BioCardia, Inc. Warrant position peaked at $30.3K in Q1 2023.
0 funds tracked by Wall St. Rank held BioCardia, Inc. Warrant as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.